Must Reads
References
15 Gamma–Delta T‐cell Lymphomas
Introduction
Epidemiology and Risk Factors
Biology of Primary Cutaneous Gamma–Delta T‐cell Lymphoma
Must Reads
References
16 Enteropathy‐Associated and Monomorphic Epitheliotropic Intestinal T‐cell Lymphomas
Introduction
Enteropathy‐associated T‐cell Lymphoma
Refractory Celiac Disease
Monomorphic Epitheliotropic Intestinal T‐Cell Lymphoma
Must Reads
References
17 Hepatosplenic T‐cell Lymphomas
Epidemiology and Disease Incidence
Basic Principles of Disease Biology
Clinical Features
Management of Disease in the Front Line
Management of the Relapsed or Refractory Disease
Splenectomy
Future Directions
Funding
Must Reads
References
18 Cutaneous T‐cell Lymphoma
Introduction
Epidemiology and Risk Factors
Basic Principles of Disease Biology
Clinical, Pathologic, and Immunophenotypic Findings
Management of Front‐Line Mycosis Fungoides/Sézary Syndrome
Management of Relapsed or Refractory Disease with Mycosis Fungoides/Sézary Syndrome
Front‐Line Management of Non‐mycosis Fungoides Cutaneous T‐cell Lymphomas
Management of Relapsed or Refractory Non‐mycosis Fungoides Cutaneous T‐cell Lymphomas
Future Directions
Must Reads
References
19 Other Rare Subtypes of Peripheral T‐cell Lymphoma
Introduction
Chronic Lymphoproliferative Disorders of Natural Killer Cells
Epstein–Barr Virus‐associated T‐cell and NK‐cell Lymphoproliferative Disorders of Childhood
Future Directions
Must Reads
References
9 Part IV: Treatment of the PTCL 20 Standard Front‐line Therapies Introduction Initial Workup and Risk Stratification Front‐line Therapy Must Reads References 21 Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin Introduction Challenges in Developing New Drugs in Peripheral T‐cell Lymphomas Drugs Approved by the US Food and Drug Administration with an Indication in Relapsed/Refractory Peripheral T‐cell Lymphoma Drugs Approved by the US Food and Drug Administration But Without An Indication in Relapsed/Refractory Peripheral T‐cell Lymphoma Drugs Approved by International Regulatory Agencies, Not Including the United States, that Carry an Indication in Relapsed/Refractory Peripheral T‐cell Lymphoma Conclusion Must Reads References 22 The Role of Autologous Stem‐cell Transplantation in Peripheral T‐cell Lymphomas Introduction Autologous Stem‐cell Transplantation in First Complete Remission Autologous Stem‐cell Transplantation in Relapsed/Refractory Disease Interpretation of Available Literature Identifying the Most Relevant Determinants for Survival among Patients with Peripheral T‐cell Lymphoma Undergoing Autologous Stem‐cell Transplantation Status of Response Prior to Autologous Stem‐cell Transplantation Risk of Stage Number of Prior Therapies and Refractory Disease Autologous
